Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTP1 | P09211 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.40 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.40 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.40 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.40 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.40 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6050365 | 0.92 | CYP1A2 (0.43) | GSTP1ALDH1A1CYP2A6CYP3A4CYP1A2 | |
| SCHEMBL7188354 | 0.91 | RELA (0.42) | GSTP1ALDH1A1CYP2A6CYP3A4CYP1A2 | |
| SCHEMBL1359561 | 0.91 | ESR1 (0.47) | GSTP1ALDH1A1CYP2A6CYP3A4CYP1A2 | |
| SCHEMBL7189743 | 0.89 | ALDH1A1 (0.49) | GSTP1ALDH1A1CYP2A6CYP1A2CYP2D6 | |
| SCHEMBL7189972 | 0.86 | MAPT (0.44) | GSTP1ALDH1A1CYP2A6CYP1A2CYP1A1 | |
| SCHEMBL7189216 | 0.85 | ESR1 (0.55) | ESR1ESR2 | |
| SCHEMBL7189223 | 0.85 | ESR1 (0.55) | ESR1ESR2 | |
| SCHEMBL7191254 | 0.85 | ESR1 (0.44) | GSTP1ALDH1A1CYP2A6ESR1ESR2 | |
| SCHEMBL7182654 | 0.85 | ALOX5 (0.43) | GSTP1ALDH1A1CYP2A6ESR1HSD17B10 | |
| SCHEMBL6050136 | 0.84 | ESR1 (0.50) | GSTP1CYP2A6CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105541-B2 | Naphthyl compounds, intermediates, compositions, and methods of use | ELI LILLY AND COMPANY (US) | 2006-09-12 | — | — | US | disclosed |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2005-03-10 | — | — | US | disclosed |
| US-6812244-B2 | POSTMENOPAUSAL OSTEOPOROSIS | ELI LILLY AND COMPANY | 2004-11-02 | — | — | US | disclosed |
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | BRYANT HENRY UHLMAN (US) | 2004-04-15 | — | — | US | disclosed |
| EP-0835867-B1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | LILLY CO ELI (US) | 2003-12-03 | — | — | EP | disclosed |
| US-6593345-B1 | Inhibiting bone loss or bone resorption comprising administering to a patient in need thereof an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt or solvate, and anticholesterol agents | ELI LILLY AND COMPANY | 2003-07-15 | — | — | US | disclosed |
| EP-0826679-B1 | Naphthyl compounds and compositions | LILLY CO ELI (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1142862-A2 | Naphthyl and tetralone derivatives as intermediates | ELI LILLY AND COMPANY (US) | 2001-10-10 | — | — | EP | disclosed |
| US-5916916-A | USEFUL AS SELECTIVE ESTROGEN RECEPTOR MODULATORS. | ELI LILLY AND COMPANY (US) | 1999-06-29 | — | — | US | disclosed |
| EP-0835867-A1 | 1-Aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods | ELI LILLY AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| WO-1998008797-A1 | NAPHTHYL COMPOUNDS, INTERMEDIATES, COMPOSITIONS, AND METHODS OF USE | ELI LILLY AND COMPANY (US) | 1998-03-05 | — | — | WO | disclosed |
| EP-0826679-A2 | Naphthyl compounds, intermediates, compositions, and method of use | ELI LILLY AND COMPANY (US) | 1998-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072820-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | GSTP1 2360/4885ALDH1A1 2018/4885CYP2A6 109/4885 |
| US-20050054632-A1 | Naphthyl compounds, intermediates, compositions, and methods of use | SQLE, NQO1, CYP3A43 | GSTP1 2360/4885ALDH1A1 2018/4885CYP2A6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.